Treatment of Dry Eye With Supplements
NCT01364311 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2015-04-15
Summary
Dry eye syndrome (DES) is a highly prevalent ocular condition inducing an inflammatory response on the ocular surface. Common symptoms include ocular discomfort, visual impairment and instability of the tear film with potential damage to the ocular surface.
In addition, an intact tear film is important to provide a smooth optical surface, to act as a barrier to pathogens, to nourish the epithelial cells of the ocular surface and to prevent exsiccation. Alterations in the tear film composition, which can have their origin in several conditions, lead to tear film hyperosmolarity or instability resulting in DES.
Regardless of the cause of DES, chronic dryness of the ocular surface leads to an increased susceptibility to oxidative stress, which is triggered by reactive oxygen species (ROS). This results in cell damage and activation of the immune system, keeping up inflammatory processes . In order to prevent ROS damage, several micronutrients such as vitamin C, E, and certain carotenoids, omega-3 free fatty acids, flavonoids and minerals have been used because of their antioxidant capacities.
Based on this knowledge the potential of these antioxidant dietary supplements has been discussed as a treatment option for DES. Preliminary data support the hypothesis that antioxidant supplementations, in particular, supplementation with omega 3 fatty acids may be beneficial for patients with DES.
The purpose of the present study is to test the hypothesis that treatment with dietary supplements improves subjective and objective symptoms of DES.
Conditions
- Dry Eye Syndromes
Interventions
- DIETARY_SUPPLEMENT
-
Vitamac® Tag and Nacht capsules
Vitamac® Tag und Nacht Kapseln: Dosage 1 capsule Vitamac® Tag per day ingested in the morning, 1 capsule Vitamac® Nacht per day ingested in the evening. Vitamac® Tag: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, ginkgo biloba 10mg, Flavinoids 25mg, Fishoil 300mg, administered for 12 weeks Vitamac® Nacht: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selen 20µg, Ginkgo Biloba 10mg, Flavinoids 25mg, Alpha Lipon acid 150mg), administered for 12 weeks
Sponsors & Collaborators
-
Medical University of Vienna
lead OTHER
Principal Investigators
-
Doreen Schmidl, MD · Department of Clinical Pharmacology,Medical University of Vienna
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2011-07-31
- Primary Completion
- 2014-11-30
- Completion
- 2014-11-30
Countries
- Austria
Study Locations
More Related Trials
-
Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects
NCT01970917 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Single Instillation of Three Different Topical Lubricants on Tear Film Thickness in Patients With Dry Eye Syndrome
NCT03161080 ·Status: COMPLETED ·Phase: NA
-
Effect of Lipid Based Eye Drops on Tear Film Lipid Layer Thickness
NCT03399292 ·Status: COMPLETED
-
Added Benefits of Lachrymal Substitute Gel During the Night in Patients With Moderate to Severe Dry Eye Syndrome
NCT02585648 ·Status: COMPLETED ·Phase: NA
-
PMCF Study to Evaluate Performance and Safety of "Distilled Waters-based Eyedrops" Used to Relieve Dry Eye Symptoms
NCT05825586 ·Status: COMPLETED ·Phase: NA
-
The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy
NCT01579539 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Corneal Residence Time of Chitosan-N-acetylcysteine Eye Drops in Patients With Dry Eye Syndrome After Single and Multiple Instillation
NCT01753752 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Efficacy of Dry Eye (DE) Disease Treatment Using Novel Tear Film Imager (TFI)
NCT04670263 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome
NCT02585453 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye
NCT00883649 ·Status: COMPLETED ·Phase: NA
-
PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms
NCT05825599 ·Status: COMPLETED ·Phase: NA
-
PMCF Study to Evaluate Performance and Safety of "Ocular Drops Based Upon Carmellose" Used to Relieve Dry Eye Symptoms
NCT05825352 ·Status: COMPLETED ·Phase: NA
-
Study on Safety and Performance of an Artificial Tear in Dry Eye Treatment in Subjects With Ocular Surface Inflammation
NCT04633863 ·Status: COMPLETED ·Phase: NA
-
Reproducibility of Tearfilm Osmolarity Measurements Using TearLab® in Patients With Dry Eye Syndrome and Healthy Subjects
NCT01744457 ·Status: COMPLETED ·Phase: NA
-
Assessment of Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Subjects While Wearing Contact Lenses and Before Insertion of Contact Lenses
NCT01747616 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease
NCT00758784 ·Status: COMPLETED ·Phase: PHASE2
-
Tear Osmolarity Clinical Utility in Dry Eye Disease
NCT02417116 ·Status: COMPLETED ·Phase: NA
-
Difference in the Frequency of Use of Lachrymal Substitutes in Patients With Moderate to Severe Dry Eye Syndrome
NCT02980913 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease
NCT05865457 ·Status: RECRUITING ·Phase: NA
-
Local Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers
NCT01278784 ·Status: COMPLETED ·Phase: PHASE1
-
A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease
NCT07078955 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Efficacy of Lipid-containing Artificial Tears in the Treatment of Dry Eye
NCT06955585 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease
NCT00404131 ·Status: COMPLETED ·Phase: PHASE3
-
Influence of Perfluorohexyloctane (NovaTears) on Tear Film Thickness in Patients With Mild to Moderate Dry Eye Disease
NCT03048526 ·Status: COMPLETED ·Phase: NA
-
Local Tolerability and Safety of Povidone K25 Eye Drops (Artificial Tears Containing Povidone) Versus Placebo in Healthy Volunteers
NCT00135824 ·Status: COMPLETED ·Phase: PHASE4